Cariprazine in Bipolar Disorders

Tohen, Mauricio

doi:10.4088/jcp.14com09606

Search citation statements

Order By: Relevance

Paper Sections

Select...

Introduction1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2021

Publication Types

Select...

Article1

Relationship

Self Cite1

Independent0

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has FDA approval for the treatment of schizophrenia (1.5–6 mg/d), acute manic/mixed episodes (3–6 mg/d), and depressive episodes associated with bipolar disorder depression (1.5–3mg/day). 30 , 31 In the European Union, it has only been approved for schizophrenia.…”

Section: Introductionmentioning

confidence: 99%

Cariprazine as a Treatment Option for Depressive Episodes Associated with Bipolar 1 Disorder in Adults: An Evidence-Based Review of Recent Data

Tohen

2021

DDDT

Self Cite

View full text Add to dashboard Cite

Depressive episodes, the most frequent episodes in bipolar disorder, contribute in large part to poor functional outcomes. Very few treatments, however, have been approved by the Food and Drug Administration for the treatment of bipolar depression. Cariprazine, a broad-spectrum dopamine antagonist/partial agonist with dopamine D3/D2 (preferring D3) and serotonin 5-HT1A receptor partial agonist properties, was recently approved. A review of the literature suggests that it is an effective and well-tolerated treatment for bipolar depression.

show abstract

Section: Introductionmentioning

confidence: 99%